leisure time -WSS

leisure time

author：comprehensive 2025-09-27 16:48:16 - browse：52551

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Brain 'hot spot' may explain why African Americans feel greater pain

WSS

These geoengineering technologies could help combat the climate crisis, scientists say

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

Cancer, immunology, HIV research ensnared in fetal tissue politics

Readout Newsletter: Illumina, CRISPR, Regeneron

Medical devices makers are asking for forgiveness, not permission

Adam's Take: Intra

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Apple is now the first public company to be valued at $3 trillion

Bacterial infection may be ‘key event’ in endometriosis, study says

Bright Health sells Medicare Advantage business to Molina

Doctor appointment wait times are getting worse

23andMe had bad news about my health. I wish a person had delivered it

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

How one medical school became remarkably diverse

6 surprising facts about sugar

New air purifier tech could be key to improving indoor air quality

Why is France rioting? What to know about the fatal police shooting of Nahel M

hotspot

Asbestos ban is immediate, but health effects will linger for decades

With Wegovy coverage, Medicare patients may face high costs

Mirador, a new biotech startup, launches with $400 million

With Wegovy coverage, Medicare patients may face high costs

Make 'food is medicine' a key part of White House nutrition meeting

Can food be medicine? And other questions about a new push

knowledge

hotspot

focus

Wikipedia